US › Healthcare

Sol Gel Technologies Ltd (SLGL)

US · Healthcare · Biotechnology

$64.54+1.73%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$591,000

Revenue YoY

-96.6%

Net profit

$-3.7M

Profit YoY

-131.7%

EPS

$-1.13

EPS estimate

$-2.31

Net margin

-622.8%

EPS came in at -1.13 against a street estimate of -2.31 — a beat of 51.1%.

Key statistics

Market cap

$215.9M

Forward P/E

9.3

P/B

4.48

Book value

$14.69

EPS (TTM)

$-5.62

52-week high

$97.97

52-week low

$23.15

50-day MA

$77.97

200-day MA

$70.03

Beta

1.13

Analyst view

Analysts rate Sol Gel Technologies Ltd a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $196.67.

Shareholding

Insiders

59.61%

Institutions

43.05%

Largest institutional holders

Fund	Stake
Opaleye Management Inc	15.27%
Great Point Partners LLC	8.38%
Phoenix Financial Ltd	4.46%
Trails Edge Capital Partners, LP	4.26%
Affinity Asset Advisors, LLC	2.59%
Squadron Capital Management LLC	1.59%
Citadel Advisors Llc	0.99%
Stonepine Capital Management Llc	0.85%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sol Gel Technologies Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.